GeneBioTech Co. ,Ltd (KOSDAQ:086060)
South Korea flag South Korea · Delayed Price · Currency is KRW
4,825.00
0.00 (0.00%)
At close: Sep 11, 2026

GeneBioTech Co. ,Ltd Balance Sheet

Millions KRW. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
9,2269,58710,2798,7517,4307,430
Short-Term Investments
18,21015,31013,12513,2658,66010,360
Cash & Short-Term Investments
27,43624,89723,40422,01616,09017,790
Cash Growth
35.99%6.38%6.31%36.83%-9.56%-35.04%
Accounts Receivable
14,75012,38813,36411,58814,09010,225
Other Receivables
1,383265.33356.36180.69183.8274.85
Receivables
16,45512,98214,05311,81814,30210,371
Inventory
15,78814,07417,04114,80215,45213,676
Prepaid Expenses
21.7627.3927.2724.1625.6641.05
Other Current Assets
1,7892,7301,310621.38399.76298.05
Total Current Assets
61,48954,71155,83649,28146,26942,175
Property, Plant & Equipment
17,01816,97213,92414,15914,61514,900
Long-Term Investments
409.22,406639.43718.86484.19763.6
Goodwill
----589.54589.54
Other Intangible Assets
549.16582.66648.82632.02398.29199.07
Long-Term Deferred Tax Assets
94.5771.1266.76205.29495.41870.49
Other Long-Term Assets
322.34493.18436.81513666.71294.23
Total Assets
80,27875,63471,98866,01764,04160,368

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
4,3253,6543,3663,5403,9014,752
Accrued Expenses
1,3001,1601,077970.5649.23515.74
Short-Term Debt
10,1208,10910,8517,7049,4868,042
Current Portion of Long-Term Debt
2,9021,9242,3591,5341,159-
Current Portion of Leases
102.2776.1995.17132.9242.29112.39
Current Income Taxes Payable
286.88413.78278.37284.2714.46-
Other Current Liabilities
588.1377.37337.78347.33667.94716.5
Total Current Liabilities
19,62515,71518,36414,51315,92014,139
Long-Term Debt
4,1744,7822,4662,9952,3292,113
Long-Term Leases
149.266.38113.47135.0812.3533.57
Other Long-Term Liabilities
74.6874.6872.0768.5453.02137
Total Liabilities
24,02320,63821,01617,71218,31516,423

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
4,3054,3054,3054,3054,3054,305
Additional Paid-In Capital
14,57614,57614,57614,57614,57614,489
Retained Earnings
37,22935,88931,80329,05918,11616,190
Comprehensive Income & Other
144.53225.65288.42364.078,7298,961
Total Common Equity
56,25554,99650,97248,30545,72643,945
Shareholders' Equity
56,25554,99650,97248,30545,72643,945
Total Liabilities & Equity
80,27875,63471,98866,01764,04160,368

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
17,44814,95715,88512,50213,02910,302
Net Cash (Debt)
9,9889,9407,5199,5143,0617,488
Net Cash Growth
110.98%32.20%-20.97%210.80%-59.12%-65.62%
Net Cash Per Share
1161.411154.38873.871104.91355.50869.68
Filing Date Shares Outstanding
8.618.618.618.618.618.61
Total Common Shares Outstanding
8.618.618.618.618.618.61
Working Capital
41,86438,99637,47234,76830,34928,037
Book Value Per Share
6531.946387.015919.735609.935310.445103.62
Tangible Book Value
55,70654,41350,32347,67344,73843,157
Tangible Book Value Per Share
6468.176319.355844.375536.525195.725012.04
Land
7,0117,0117,0117,0615,4645,464
Buildings
10,98310,0846,4526,5336,4896,471
Machinery
10,14810,0979,5479,3429,2559,222
Construction In Progress
-540595.1341.651,6201,007